Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Operating Leases (2022 - 2025)

Entrada Therapeutics has reported Operating Leases over the past 4 years, most recently at $50.9 million for Q4 2025.

  • Quarterly results put Operating Leases at $50.9 million for Q4 2025, down 1.39% from a year ago — trailing twelve months through Dec 2025 was $50.9 million (down 1.39% YoY), and the annual figure for FY2025 was $50.9 million, down 1.39%.
  • Operating Leases for Q4 2025 was $50.9 million at Entrada Therapeutics, up from $48.0 million in the prior quarter.
  • Over the last five years, Operating Leases for TRDA hit a ceiling of $69.1 million in Q3 2023 and a floor of $9.1 million in Q1 2023.
  • Median Operating Leases over the past 4 years was $50.7 million (2025), compared with a mean of $45.1 million.
  • Biggest five-year swings in Operating Leases: tumbled 71.36% in 2023 and later surged 537.26% in 2024.
  • Entrada Therapeutics' Operating Leases stood at $17.5 million in 2022, then soared by 244.1% to $60.3 million in 2023, then fell by 14.38% to $51.6 million in 2024, then fell by 1.39% to $50.9 million in 2025.
  • The last three reported values for Operating Leases were $50.9 million (Q4 2025), $48.0 million (Q3 2025), and $49.3 million (Q2 2025) per Business Quant data.